Company Description
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.
The company’s marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types.
It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions.
iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jun 17, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Shahin Behroyan |
Contact Details
Address: 8 Cabot Road, Suite 1800 Woburn, Massachusetts 01801 United States | |
| Phone | 781 301 6700 |
| Website | ispecimen.com |
Stock Details
| Ticker Symbol | ISPC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 1558569 |
| CUSIP Number | 45032V306 |
| ISIN Number | US45032V3069 |
| Employer ID | 27-0480143 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Shahin Behroyan | Chief Executive Officer |
| Yuying Liang | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 14, 2026 | DEF 14A | Other definitive proxy statements |
| Sep 10, 2026 | 8-K | Current Report |
| Sep 4, 2026 | PRE 14A | Other preliminary proxy statements |
| Sep 4, 2026 | 8-K | Current Report |
| Aug 31, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 7, 2026 | 8-K | Current Report |
| Aug 7, 2026 | 424B4 | Prospectus |